Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sunvozertinib for Stage II-IIIB NSCLC With EGFR Exon 20 Insertion Mutations
NCT07274761Phase 2Active, not recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2024
- Primary completion
- May 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective Response Rate up to 30 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07274761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274761.